Growing Diagnostics Arm Supports ABT Stock, Macro Issues Ail

Abbott (ABT) reported strong Q2 2025 performance, driven by its FreeStyle Libre CGM sales exceeding $1.9 billion, up 19.6% organically, and robust growth in its Diagnostics and Established Pharmaceuticals Divisions, with biosimilar launches anticipated in 2026. However, the company faces significant macroeconomic headwinds, including rising operational costs, adverse foreign exchange impacts, and specific challenges in China due to VBP policies and its pediatric nutrition exit, which are projected to create a $700 million headwind for Diagnostics in 2025. Despite these pressures, ABT's diversified portfolio and product innovation are expected to sustain its market position.

Analysis

Abbott's Q2 2025 results highlight a bifurcated narrative, where strong performance in key growth segments is tempered by significant macroeconomic and geographical headwinds. The Diabetes Care division remains the primary growth engine, with FreeStyle Libre sales surpassing $1.9 billion, a 19.6% organic increase driven by nearly 26% growth in the United States. This momentum is further supported by a promising pipeline, including a dual-analyte sensor for ketone monitoring. The Diagnostics business also shows resilience, with Core Laboratory sales growing 8% ex-China, and the Established Pharmaceuticals Division (EPD) expanding 7.7% organically, bolstered by a biosimilar pipeline set for 2026 launches. This operational strength has propelled the stock to a 19.6% year-to-date gain, substantially outperforming the industry's 5.7% rise. However, these positives are counterbalanced by considerable pressures. Margin compression is evident, with adjusted SG&A expenses rising 5.3% year-over-year. The challenges in China are particularly acute, stemming from the ongoing exit from the pediatric nutrition market and the government's volume-based procurement (VBP) policies, which are projected to create a $700 million headwind for full-year 2025 Diagnostics sales. Furthermore, adverse foreign exchange movements created a 1.1% drag on sales in the first half of 2025, reflecting the company's significant international exposure.

Key Decisions for Investors

• Investors should weigh the robust organic growth from the FreeStyle Libre franchise against the material headwinds from China's VBP policy and persistent macroeconomic cost pressures.
• Monitor the impact of the projected $700 million revenue headwind in the Diagnostics segment and track SG&A expenses for signs of margin stabilization or further erosion.
• Consider the 2026 biosimilar launches and the new dual-analyte CGM sensor as potential long-term catalysts that could offset the current challenges in specific markets.
• Given the stock's significant year-to-date outperformance, a neutral stance may be prudent until there is greater clarity on the duration and severity of the FX and China-related pressures.